New combo therapy may shield kidney transplant patients from common virus
NCT ID NCT04934527
First seen May 13, 2026 · Last updated May 13, 2026
Summary
This study tested whether giving a special antibody (CMV-specific immunoglobulin) to kidney transplant patients who already had CMV could prevent the virus from reactivating. The approach relies on a specific type of immune cell (CD16+ gamma delta T-cells) that helps fight CMV. 42 CMV-positive adults receiving a kidney transplant took part. The goal was to see if this combination could keep CMV infection away for a year after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital Pellegrin
Bordeaux, 33000, France
Conditions
Explore the condition pages connected to this study.